Skip to content

The Therapeutic Effect of Dau-Di-Wu-Gong in Patient With Ankle Fracture

The Therapeutic Effect of Helminthostachys Zeylanica(L.)Hook on Functional Recovery After Surgical Operation in Patients With Ankle Fracture

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03805347
Enrollment
45
Registered
2019-01-15
Start date
2020-12-12
Completion date
2021-01-11
Last updated
2021-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankle Fractures

Keywords

Ankle fracture, Helminthostachys zeylanica(L.)Hook, Clinical trials, Functional recovery

Brief summary

Ankle fracture is one of most common bone fracture in Taiwan, although ankle fracture can be treated by surgical operation, local edema, pain and wound poor healing always is noted, according to the investigator's knowledge, no good therapeutic methods to treat mention-above symptoms until now. Helminthostachys zeylanica(L.)Hook, also called Dau-Di-U-Gon has anti-inflammation, calm down heat and detoxication, and anti-edema. People in Taiwan often uses Helminthostachys zeylanica(L.)Hook to treat bone and tendon pain, and its Ugonin component of Helminthostachys zeylanica(L.)Hook also is proved that has analgesia and ant-inflammation. Therefore, the purpose of the present study was to design a randomized, double-blind, controlled study to evaluate functional recovery effect of Helminthostachys zeylanica(L.)Hook after surgical operation in patients with ankle fracture.

Detailed description

the purpose of the present study was to design a randomized, double-blind, controlled study to evaluate functional recovery effect of Helminthostachys zeylanica(L.)Hook after surgical operation in patients with ankle fracture. The primary outcome measure was the scores change of American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot scale, and tape (figure-of-eight) methods. Secondary outcome measure was the level changes of bone metabolism in peripheral blood, four diagnostic method, and the changes of ankle X-ray findings.

Interventions

DRUGHelminthostachys zeylanica(L.)Hook

Extract of Helminthostachys zeylanica(L.)Hook, 1gm/time, 3 times daily

DRUGStarch

Starch in capsule, 1gm/time, 3 times daily

Sponsors

Changhua Christian Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

Double-blinded randomized

Intervention model description

Treatment group and Control group

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* 20-75 year-old male or female with acute ankle fractures with surgical indication (Joint line displacement \>2mm ; fracture dislocation)

Exclusion criteria

* Previous skin disease, DM or peripheral vessel disease with local foot amputation. * Previous ankle surgery, old ankle fracture, or open fracture. * Liver or renal dysfunction, and cardiorespiratory failure. * Surgical infection after surgery. * Patient refuse or can't finish the treatment course * Patient with cancer * Pregnancy * HIV positive.

Design outcomes

Primary

MeasureTime frameDescription
Change of American Orthopedic Foot and Ankle(AOFAS) Score1st day of study, 10~14th days of study, 43th days of studyScore to evaluate ankle and hindfoot function, from 0-100 points, healthy ankle 100 points
Change of Ankle volume1st day of study, 10~14th days of study, 43th days of studyfigure-of-8 method

Secondary

MeasureTime frameDescription
Level of bone turnover marker1st day of study, 43th days of studyAlkaline Phosphatase(ALP)normal range between 37 and 116 U/L; type 1 procollagen amino-terminal-propeptide (P1NP), normal range between 20-42 ng/L
Fracture Healing1st day of study, 43th days of studyankle radiography, bone callus formation and continuity of callus

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026